207-353-1

应用筛选条件

关键词:'207-353-1'

显示 1-2 共 2 条结果关于 "207-353-1" 范围论文

DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats.

Sota Kato et al.

The Journal of pharmacology and experimental therapeutics, 372(2), 166-174 (2019-12-06)

Prolyl hydroxylase (PHD) inhibitors are being developed as alternatives to recombinant human erythropoietin (rHuEPO) for the treatment of anemia in patients with chronic kidney disease (CKD). However, the effects of PHD inhibitors and rHuEPO on blood pressure and CKD in

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Lior H Katz et al.

The Cochrane database of systematic reviews, 9(9), CD008516-CD008516 (2012-09-14)

The standard length of peginterferon plus ribavirin treatment for chronic hepatitis C virus (HCV) genotype 1 infected patients is 48 weeks. However, the number of patients demonstrating a sustained virological response is not high. In order to improve sustained virological

1/1